ProQR Therapeutics (NASDAQ:PRQR) Earns “Buy” Rating from Chardan Capital

ProQR Therapeutics (NASDAQ:PRQR)‘s stock had its “buy” rating reiterated by Chardan Capital in a research note issued to investors on Thursday,Benzinga reports. They currently have a $4.00 price target on the biopharmaceutical company’s stock. Chardan Capital’s price target suggests a potential upside of 41.34% from the company’s current price.

A number of other equities research analysts have also commented on the stock. Raymond James raised shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $6.00 to $14.00 in a report on Tuesday, October 29th. HC Wainwright raised their price target on shares of ProQR Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 8th. Finally, StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.60.

ProQR Therapeutics Stock Down 14.0 %

Shares of ProQR Therapeutics stock opened at $2.83 on Thursday. The stock has a market capitalization of $231.15 million, a P/E ratio of -8.84 and a beta of 0.24. ProQR Therapeutics has a 12-month low of $1.61 and a 12-month high of $4.62. The company has a 50-day simple moving average of $3.39 and a 200 day simple moving average of $2.38.

Institutional Trading of ProQR Therapeutics

Institutional investors have recently bought and sold shares of the business. Privium Fund Management B.V. grew its stake in shares of ProQR Therapeutics by 4.4% during the second quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock worth $9,208,000 after purchasing an additional 236,279 shares during the period. OneDigital Investment Advisors LLC boosted its holdings in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 15,550 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 7,300 shares during the period. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).